Neisseriaceae Infections - 25 Studies Found Terminated : Hormonal Contraception and Risk of Chlamydia and Gonorrhea : Chlamydia Infection Neisseriaceae Infection : 2004-09-16 : Drug: Depo Medroxyprogesterone acetate Dru Recruiting : South Australian Meningococcal B Vaccine Herd Immunity Study : Meningococcal Disease : 2017-03-17 : Biological: Licensed 4CMenB vaccine Two doses (0.5 mL each) of Bexsero ® vaccine at least 1 month t Recruiting : Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination : Infections, Meningococcal : 2016-12-06 : Biological: Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo) Recruiting : Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents : Infections, Meningococcal : 2016-10-25 : Biological: Meningococcal ABCWY Vaccine Recruiting : PRIME Follow up - Quadri Meningo Vacinees : Meningococcal Disease : 2016-06-15 : Other: venepuncture only single venepuncture Active, not recruiting : Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization : Meningococcal Infections : 2016-03-14 : Biological: 4CMenb Other Name: Active, not recruiting : Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine : Meningococcal Disease : 2015-12-21 : Biological: MenC-CRM conjugate vaccine with 12.5 ug LHD153R Active, not recruiting : Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) : Meningococcal Infections : 2015-09-30 : Biological: Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals) All subjects will receive three doses of a T Completed : A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years : MENINGOCOCCAL INFECTION : 2015-08-20 : Biological: Bivalent rLP2086 Vaccine Completed : A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158) : Meningococcal Disease : 2015-05-04 : Biological: MenABCWY+OMV vaccine Intramuscular injection of a single dose at Day 1 to subjects in the Me Next >>>